EC OKs use of Bristol-Myers' Opdivo to treat head and neck cancer

|About: Bristol-Myers Squibb C... (BMY)|By:, SA News Editor

As expected, the European Commission (EC) approves the use of Bristol-Myers Squibb's (BMY +0.5%) Opdivo (nivolumab) for the treatment of adult patients with squamous cell cancer of the head and neck who are progressing on or after platinum-based chemotherapy.

The advisory committee CHMP adopted a positive opinion backing approval a month ago.

Previously: European advisory committee backs Bristol-Myers' Opdivo for head and neck cancer (March 24)